@article{d4abed1935eb4081b0b6cf22c99eef85,
title = "Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia",
author = "Taro Kishi and Hiroshi Nakamura and Atsushi Matsuura and Nakao Iwata",
note = "Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mr. Nakamura and Mr. Matsuura are full-time employees of Sumitomo Dainippon Pharma Co., Ltd. Other authors have declared that there are no conflicts of interest relating to the subject of this study. Interests for the past 3 years are as follows: Dr. Kishi received speaker{\textquoteright}s honoraria from Sumitomo Dainippon, Otsuka, Eisai, Daiichi Sankyo, Janssen, Takeda, Kyowa, Kissei, Meiji, Pfizer, Mochida, Eli Lilly, MSD, Janssen, and Tanabe-Mitsubishi (Yoshitomi); as well as research grants from Eisai, the Japanese Ministry of Health, Labour and Welfare, Grant-in-Aid for Scientific Research (C), and Fujita Health University School of Medicine. Prof. Iwata received speaker{\textquoteright}s honoraria from Sumitomo Dainippon, Eli Lilly, Janssen, Meiji, Otsuka, Takeda, and Pfizer as well as research grants from Dainippon Sumitomo, Eisai, Otsuka, and Takeda; along with research grants from Daiichi Sankyo, Takeda, Dainippon Sumitomo Eisai, Meiji Tanabe-Mitsubishi, and Otsuka. ",
year = "2022",
month = feb,
doi = "10.1016/j.schres.2021.12.047",
language = "English",
volume = "240",
pages = "231--232",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier B.V.",
}
SDG 3 Good Health and Well-being